Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A4 | P31645 | 2/20 | 0.46 |
| ▸ | CHRNB2 | P17787 | 3/20 | 0.43 |
| ▸ | CHRNA4 | P43681 | 2/20 | 0.43 |
| ▸ | NOS1 | P29475 | 4/20 | 0.41 |
| ▸ | NOS3 | P29474 | 2/20 | 0.41 |
| ▸ | NOS2 | P35228 | 2/20 | 0.41 |
| ▸ | CHRNB4 | P30926 | 5/20 | 0.41 |
| ▸ | CHRNA3 | P32297 | 5/20 | 0.41 |
| ▸ | CHRM3 | P20309 | 2/20 | 0.40 |
| ▸ | CHRNB1 | P11230 | 1/20 | 0.40 |
| ▸ | CHRNB3 | Q05901 | 1/20 | 0.40 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8793039 | 0.85 | CHRNB4 (0.49) | SLC6A4CHRNB2CHRNA4CHRNB4CHRNA3 | |
| SCHEMBL11319093 | 0.81 | CYP1A2 (0.54) | SLC6A4CHRNB2CHRNB4CHRNA3CHRM3 | |
| SCHEMBL659411 | 0.78 | ADRA2A (0.52) | SLC6A4CHRNB4CHRNA3ADRA2A | |
| SCHEMBL4127495 | 0.78 | ADRA2A (0.52) | SLC6A4CHRNB4CHRNA3ADRA2A | |
| SCHEMBL3381424 | 0.78 | SLC6A4 (0.71) | SLC6A4ADRA2A | |
| SCHEMBL3381418 | 0.78 | SLC6A4 (0.71) | SLC6A4ADRA2A | |
| SCHEMBL11322419 | 0.77 | DRD1 (0.47) | SLC6A4CHRNB4CHRNA3ADRA2A | |
| Hydrochloric Acid SCHEMBL11325289 | 0.77 | ADRA2A (0.51) | SLC6A4CHRNB4CHRNA3ADRA2A | |
| SCHEMBL11379296 | 0.77 | HTR6 (0.47) | CHRNB2CHRNA4CHRNB4CHRNA3CHRNB1 | |
| SCHEMBL11324634 | 0.76 | DRD1 (0.44) | SLC6A4CHRNB2CHRNA4CHRNB4CHRNA3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2681221-B1 | TRICYCLIC INHIBITORS OF KINASES | ABBVIE INC (US) | 2016-05-18 | — | — | EP | disclosed |
| US-8710065-B2 | Tricyclic inhibitors of kinases | ABBVIE INC. (US) | 2014-04-29 | — | — | US | disclosed |
| US-20120220572-A1 | TRICYCLIC INHIBITORS OF KINASES | ABBOTT LABORATORIES (US) | 2012-08-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120220572-A1 | TRICYCLIC INHIBITORS OF KINASES | WEE1, WEE2, CDK1 | SLC6A4 4255/4885CHRNB2 4591/4885CHRNA4 4406/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.